Atlas Trials

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Clinical trial NCT05932290 · COMPLETED

Trial details

NCT number
NCT05932290
Sponsor
Pfizer
Status
COMPLETED
Study type
OBSERVATIONAL
Multiple Myeloma
Start date
2023-06-01
Primary completion
2023-07-12
Enrollment
514

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.